Lutein and Alzheimer's Disease Study

Alzheimer's Disease Clinical Trial

— LAD  

Official title:

Lutein and Oxidative Stress in Alzheimer's Disease - A Pilot Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00596024
• Other study ID #: LAD
• Secondary ID: Alzheimer resear
• Status: Terminated
• Phase: Phase 2
• Start date: December 2007
• Est. completion date: July 2009

Study information

• Verified date: August 2019
• Source: Oregon Health and Science University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Oxidative damage by free radicals may be involved in causing Alzheimer's disease (AD). Free radicals may lead to death of nerve cells and decline in brain function. Certain antioxidants may suppress this free radical damage associated with AD. Carotenoids are a family of naturally occurring antioxidants that have important functions for human health. Carotenoids are known to reduce oxidative damage, but their effects have not been studied in AD patients.

The objective of the study is to examine whether lutein supplementation helps to reduce oxidative damage from free radicals in AD patients.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 3
• Est. completion date: July 2009
• Est. primary completion date: July 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 55 Years and older

Eligibility

Inclusion Criteria:

• Diagnosed with moderately severe Alzheimer's disease

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease

Intervention

Dietary Supplement:
• lutein/zeaxanthin
daily supplementation of lutein and zeaxanthin at dose of 12 mg/day
• placebo
placebo capsules with the same size and coating as those of lutein/zeaxanthin supplements without active ingredients

Locations

Country	Name	City	State
United States	Oregon Health and Science University	Portland	Oregon

Sponsors (2)

Lead Sponsor	Collaborator
Oregon Health and Science University	Oregon Partnership for Alzheimer's Research

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	oxidative damage markers		3 months